AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11844417 — intervention group
Group type: EXPERIMENTAL
Intervention: Efferdent
Number of subjects: 0
Study 11844417 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 0
Study 9972772 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 at a dose of 0.02 microg x kg(‐1) x min(‐1) (PG20 group)
Number of subjects: 83
Study 9972772 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 at a dose of 0.05 microg x kg(‐1) x min(‐1) (PG50 group)
Number of subjects: 83
Study 9972772 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PGE1)
Number of subjects: 83
Study 8775774 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally applied vaginal conjugated estrogen cream
Number of subjects: 67
Study 8775774 — intervention group
Group type: COMPARATOR
Intervention: Atrophic vaginitis
Number of subjects: 67
Study 2206018 — intervention group
Group type: EXPERIMENTAL
Intervention: Norinyl 1 + 35
Number of subjects: 300
Study 2206018 — intervention group
Group type: COMPARATOR
Intervention: Norinyl 1 + 50
Number of subjects: 300
Study 6126013 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 24
Study 6126013 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluroxene
Number of subjects: 24
Study 6126013 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 24
Study 6126013 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide-barbiturate-narcotic (Control)
Number of subjects: 24
Study 31483146 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical breast pumps
Number of subjects: 50
Study 31483146 — intervention group
Group type: COMPARATOR
Intervention: Hand expression
Number of subjects: 50
Study 31483146 — intervention group
Group type: COMPARATOR
Intervention: Direct breastfeeding
Number of subjects: 50
Study 28106471 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.1% bromfenac sodium
Number of subjects: 60
Study 28106471 — intervention group
Group type: COMPARATOR
Intervention: Control placebo
Number of subjects: 60
Study 25663312 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-array imaging mode
Number of subjects: 30
Study 25663312 — intervention group
Group type: EXPERIMENTAL
Intervention: Array imaging mode
Number of subjects: 30
Study 25663312 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition imaging mode
Number of subjects: 30
Study 25663312 — intervention group
Group type: EXPERIMENTAL
Intervention: TBS
Number of subjects: 30
Study 25663312 — intervention group
Group type: EXPERIMENTAL
Intervention: BMD
Number of subjects: 30
Study 25663312 — intervention group
Group type: COMPARATOR
Intervention: Imaging modes comparison
Number of subjects: 30
Study 24396024 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg for 8 weeks
Number of subjects: 60
Study 24396024 — intervention group
Group type: COMPARATOR
Intervention: Control group (ongoing antihypertensive treatment)
Number of subjects: 60
Study 24396024 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone and Control
Number of subjects: 60
Study 18381951 — intervention group
Group type: EXPERIMENTAL
Intervention: DMXAA (doses of 6 to 4,900 mg/m², administered as a 20-minute i.v. infusion weekly or every 3 weeks)
Number of subjects: 124
Study 18381951 — intervention group
Group type: EXPERIMENTAL
Intervention: DMXAA
Number of subjects: 124
Study 14741299 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe-standing
Number of subjects: 10
Study 14741299 — intervention group
Group type: COMPARATOR
Intervention: Heel-toe standing
Number of subjects: 10
Study 10842410 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat lift training
Number of subjects: 36
Study 10842410 — intervention group
Group type: EXPERIMENTAL
Intervention: Free weight resistance training
Number of subjects: 36
Study 10842410 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 9338928 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 31
Study 9338928 — intervention group
Group type: COMPARATOR
Intervention: Control group (mechanical spinal disease)
Number of subjects: 31
Study 8115560 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind counselor (described as a blind doctoral student)
Number of subjects: 0
Study 8115560 — intervention group
Group type: COMPARATOR
Intervention: Control group (informed that the counselor was a doctoral student)
Number of subjects: 0
Study 3758367 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally implantable Infusaid‐400 pumps
Number of subjects: 39
Study 3758367 — intervention group
Group type: COMPARATOR
Intervention: Implantable ports
Number of subjects: 39
Study 31781758 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective urine testing for TB diagnostics
Number of subjects: 322
Study 31781758 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (retrospective urine testing)
Number of subjects: 322
Study 28409660 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (100 mg twice daily)
Number of subjects: 42
Study 28409660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 25981836 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80
Study 25981836 — intervention group
Group type: COMPARATOR
Intervention: Control (Normal Saline)
Number of subjects: 80
Study 23772682 — intervention group
Group type: EXPERIMENTAL
Intervention: FRDMS
Number of subjects: 48
Study 23772682 — intervention group
Group type: EXPERIMENTAL
Intervention: FRD
Number of subjects: 48
Study 23772682 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 23503992 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on response accuracy
Number of subjects: 71
Study 23503992 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback‐plus (response accuracy plus correct answer)
Number of subjects: 71
Study 23503992 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct instruction
Number of subjects: 71
Study 19321521 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional one‐hour session of task‐specific motor training for the hand five times a week over a six‐week period
Number of subjects: 39
Study 19321521 — intervention group
Group type: COMPARATOR
Intervention: Standard care consisting of 10 minutes of hand therapy three times a week
Number of subjects: 39
Study 17705092 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG) with D2 lymph node dissection
Number of subjects: 64
Study 17705092 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy with D2 lymph node dissection (from pilot study)
Number of subjects: 64
Study 15803229 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy within 24 hours of admission
Number of subjects: 40
Study 15803229 — intervention group
Group type: COMPARATOR
Intervention: Delayed laparoscopic cholecystectomy (6 to 12 weeks later)
Number of subjects: 40
Study 11339782 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg suppository
Number of subjects: 48
Study 11339782 — intervention group
Group type: COMPARATOR
Intervention: No diclofenac suppository (Control)
Number of subjects: 48
Study 9238893 — intervention group
Group type: EXPERIMENTAL
Intervention: Rota‐dent, Pro‐Dentec Inc.
Number of subjects: 35
Study 9238893 — intervention group
Group type: COMPARATOR
Intervention: Interplak, Bausch and Lomb Inc.
Number of subjects: 35
Study 8431589 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation programme
Number of subjects: 261
Study 8431589 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 261
Study 2890728 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg APM/kg body weight
Number of subjects: 18
Study 2890728 — intervention group
Group type: COMPARATOR
Intervention: Unsweetened beverage
Number of subjects: 18
Study 2890728 — intervention group
Group type: COMPARATOR
Intervention: 4 mg/kg body weight as aspartame (APM)
Number of subjects: 18
Study 29417877 — intervention group
Group type: EXPERIMENTAL
Intervention: GENEActiv accelerometer at baseline and 18-month follow-up
Number of subjects: 886
Study 27565253 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase support using vaginal progesterone gel (n = 202)
Number of subjects: 393
Study 27565253 — intervention group
Group type: COMPARATOR
Intervention: No luteal phase support (n = 191)
Number of subjects: 393
Study 24002227 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral therapy (CBT) based on the modified Coping Cat Program
Number of subjects: 24
Study 24002227 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual intervention
Number of subjects: 24
Study 22247123 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg every 12 hours)
Number of subjects: 1184
Study 22247123 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (15 mg/kg every 12 hours)
Number of subjects: 1184
Study 22247123 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 1184
Study 22247123 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 1184
Study 20674827 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (n = 28)
Number of subjects: 102
Study 20674827 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 26)
Number of subjects: 102
Study 20674827 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 microg daily)
Number of subjects: 102
Study 18235151 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate (300 mg/d)
Number of subjects: 40
Study 18235151 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg/d)
Number of subjects: 40
Study 15963401 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal continuous positive airway pressure (CPAP) treatment
Number of subjects: 17
Study 15963401 — intervention group
Group type: COMPARATOR
Intervention: No CPAP (control)
Number of subjects: 17
Study 14673984 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 2 mg
Number of subjects: 464
Study 14673984 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 3 mg
Number of subjects: 464
Study 14673984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study 11166502 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior Professor (SP) intervention, utilizing experienced clinical and managerial staff for program induction seminars during the first weeks of admissions.
Number of subjects: 605
Study 11166502 — intervention group
Group type: COMPARATOR
Intervention: Standard or non-enhanced treatment (control group).
Number of subjects: 605
Study 8996671 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration exposure (3-12 m/s²) with varying directions (Xh, Yh, Zh) and grip forces (25-75 N)
Number of subjects: 84
Study 8996671 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual biological factors (age, hand volume, hand thickness)
Number of subjects: 84
Study 8996671 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure
Number of subjects: 84
Study 8996671 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective symptoms (finger blanching, numbness) and nicotine use
Number of subjects: 84
Study 1479133 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 h of morning light treatment (about 7000 lux)
Number of subjects: 32
Study 1479133 — intervention group
Group type: COMPARATOR
Intervention: 1 h of morning placebo treatment (deactivated negative ion generator)
Number of subjects: 32
Study 6361287 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose methylprednisolone (1,000-mg bolus and daily thereafter for ten days)
Number of subjects: 330
Study 6361287 — intervention group
Group type: COMPARATOR
Intervention: Standard dose methylprednisolone (100-mg bolus and daily thereafter for ten days)
Number of subjects: 330
Study 6361287 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose methylprednisolone
Number of subjects: 330
Study 31345170 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling for caregivers and multicomponent therapy for cognitively impaired persons in day-care centers.
Number of subjects: 359
Study 30189000 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic home medication review tool (before admission)
Number of subjects: 65
Study 30189000 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic home medication review tool (after admission)
Number of subjects: 65
Study 26826544 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB
Number of subjects: 264
Study 26826544 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo followed by MenACWY‐CRM)
Number of subjects: 264
Study 24603863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 64
Study 24603863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 22409245 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive gaming program (n=22)
Number of subjects: 44
Study 22409245 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (n=22)
Number of subjects: 44
Study 20965863 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture repair in small hernia (n = 247)
Number of subjects: 953
Study 20965863 — intervention group
Group type: COMPARATOR
Intervention: Mesh repair in small hernia (n = 247)
Number of subjects: 953
Study 20965863 — intervention group
Group type: EXPERIMENTAL
Intervention: Onlay mesh reconstruction in large hernia (n = 224)
Number of subjects: 953
Study 20965863 — intervention group
Group type: COMPARATOR
Intervention: Sublay mesh reconstruction in large hernia (n = 235)
Number of subjects: 953
Study 17686105 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy for allergic rhinoconjunctivitis
Number of subjects: 0
Study 17686105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15776297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg i.v. administered at 1 and 9 hours postoperatively
Number of subjects: 43
Study 15776297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 15776297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg i.v.
Number of subjects: 43
Study 12039480 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer for primary PTCA
Number of subjects: 138
Study 12039480 — intervention group
Group type: COMPARATOR
Intervention: On-site thrombolysis
Number of subjects: 138
Study 9659670 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine application (17.5 mg day‐1)
Number of subjects: 0
Study 9659670 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine application (35 mg day‐1)
Number of subjects: 0
Study 9659670 — intervention group
Group type: COMPARATOR
Intervention: Baseline (predefaecation)
Number of subjects: 0
Study 8087519 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/m2 cisplatin weekly + radiotherapy
Number of subjects: 331
Study 8087519 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/m2 cisplatin daily + radiotherapy
Number of subjects: 331
Study 8087519 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 331
Study 2789927 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of oxytocin (0.33 u min‐1)
Number of subjects: 10
Study 2789927 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of oxytocin
Number of subjects: 10
Study 788739 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone 50 mg/day
Number of subjects: 7
Study 788739 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone 100 mg/day
Number of subjects: 7
Study 788739 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone 200 mg/day
Number of subjects: 7
Study 788739 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone 300 mg/day
Number of subjects: 7
Study 30760127 — intervention group
Group type: EXPERIMENTAL
Intervention: English listeners estimating age from English speakers
Number of subjects: 0
Study 30760127 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese listeners estimating age from English speakers
Number of subjects: 0
Study 30760127 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese listeners estimating age from Japanese speakers
Number of subjects: 0
Study 30760127 — intervention group
Group type: EXPERIMENTAL
Intervention: English listeners estimating age from Japanese speakers
Number of subjects: 0
Study 30760127 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups of listeners estimating age based on speaker characteristics
Number of subjects: 0
Study 31388932 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib plus dexamethasone (Kd) twice-weekly (56 mg/m2)
Number of subjects: 158
Study 31388932 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib plus dexamethasone (Vd)
Number of subjects: 158
Study 31388932 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib plus dexamethasone (Kd) once-weekly (70 mg/m2)
Number of subjects: 158
Study 31388932 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib plus dexamethasone (Kd) twice-weekly (27 mg/m2)
Number of subjects: 158
Study 31388932 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib (both dosing regimens)
Number of subjects: 158
Study 29207479 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: mother's own milk (MOM) and donor milk (unfortified)
Number of subjects: 109
Study 29207479 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: MOM (unfortified) and preterm formula
Number of subjects: 109
Study 29207479 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: MOM (start fortification >50 mL/day) and preterm formula
Number of subjects: 109
Study 29207479 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intake of phosphorus (P)
Number of subjects: 109
Study 29207479 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intake of calcium (Ca)
Number of subjects: 109
Study 29207479 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between Ca and P intake
Number of subjects: 109
Study 29207479 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of human milk per kg during the first 10 days
Number of subjects: 109
Study 29207479 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of Ca and P during the first 10 days
Number of subjects: 109
Study 25581604 — intervention group
Group type: EXPERIMENTAL
Intervention: NLFU + Standard Care (SC)
Number of subjects: 112
Study 25581604 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 112
Study 25581604 — intervention group
Group type: EXPERIMENTAL
Intervention: NLFU + SC
Number of subjects: 112
Study 25581604 — intervention group
Group type: COMPARATOR
Intervention: SC
Number of subjects: 112
Study 23641026 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Gait Index (DGI)
Number of subjects: 81
Study 23641026 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-Foot Timed Walk Test
Number of subjects: 81
Study 23641026 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Impact Scale (psychological subscale)
Number of subjects: 81
Study 22283892 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 months daily rifampin (4RMP)
Number of subjects: 20000
Study 22283892 — intervention group
Group type: COMPARATOR
Intervention: 9 months daily isoniazid (9INH)
Number of subjects: 20000
Study 22283892 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 20000
Study 19585672 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime sleep for 1 hour
Number of subjects: 0
Study 19585672 — intervention group
Group type: COMPARATOR
Intervention: Wake condition (control)
Number of subjects: 0
Study 16389540 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 2 weeks
Number of subjects: 0
Study 16389540 — intervention group
Group type: EXPERIMENTAL
Intervention: Gram-negative organisms
Number of subjects: 0
Study 15541850 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhophylac 300 (300 microg dose) administered either intravenously or intramuscularly
Number of subjects: 432
Study 11110260 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesion preventing techniques
Number of subjects: 0
Study 11110260 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical intervention
Number of subjects: 0
Study 9372670 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized DSCG 20 mg every 6 hours from Day 3 to Day 28
Number of subjects: 26
Study 9372670 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 cc NS) every 6 hours from Day 3 to Day 28
Number of subjects: 26
Study 9372670 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized DSCG 20 mg
Number of subjects: 26
Study 9372670 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 cc NS)
Number of subjects: 26
Study 1609045 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine 0.5 mg daily
Number of subjects: 29
Study 3980808 — intervention group
Group type: EXPERIMENTAL
Intervention: Unna's boots
Number of subjects: 21
Study 3980808 — intervention group
Group type: COMPARATOR
Intervention: Elastic support stockings
Number of subjects: 21
Study 3592142 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized MgSO4
Number of subjects: 9
Study 3592142 — intervention group
Group type: COMPARATOR
Intervention: NaCl (saline)
Number of subjects: 9
Study 31943843 — intervention group
Group type: EXPERIMENTAL
Intervention: U5MTase (uracil‐5‐methyltransferase) identified in Plasmodium falciparum (Pf, strain Pf3D7)
Number of subjects: 300000000
Study 31943843 — intervention group
Group type: EXPERIMENTAL
Intervention: In silico drug screening for potential inhibitory drug molecules
Number of subjects: 300000000
Study 30427061 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior thalamic nucleus deep brain stimulation
Number of subjects: 18
Study 30427061 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stimulation during the first 6 months)
Number of subjects: 18
Study 27281754 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification surgery
Number of subjects: 33
Study 26645515 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion therapy (Group A)
Number of subjects: 56
Study 22481046 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Number of subjects: 1421
Study 22481046 — intervention group
Group type: COMPARATOR
Intervention: IVUS-non-guided PCI
Number of subjects: 1421